Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer

Clinical trial NCT04250545 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04250545
Sponsor: National Cancer Institute (NCI)
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Leptomeningeal Neoplasm Metastatic Lung Non-Small Cell Carcinoma Metastatic Malignant Neoplasm in the Brain Recurrent Lung Non-Small Cell Carcinoma Stage IV Lung Cancer AJCC v8 Stage IVA Lung Cancer AJCC v8 Stage IVB Lung Cancer AJCC v8

Start date: 2020-10-26
Primary completion: 2025-11-21
Enrollment: 22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.